Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study
Open Access
- 2 September 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 65 (11) , 2445-2449
Abstract
To compare plasma antiretroviral concentrations in HIV-HCV co-infected and in matched HIV mono-infected patients. This was a cross-sectional, observational study. Antiretroviral trough concentrations (Cmin) in plasma were measured in HIV-HCV co-infected patients with liver disease documented by liver biopsy, matched with HIV mono-infected patients according to gender and antiretroviral treatment. Cmin values in serum were measured using an HPLC method. Statistical analysis was performed using the Wilcoxon test. Seventy-three HIV-HCV co-infected patients and 66 HIV-infected patients were enrolled; 70% of patients were receiving a protease inhibitor (PI)- and 30% a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen. Among the 73 co-infected patients, 27 had a fibrosis score (Fibrotest®) of F4. Abacavir was the only nucleoside reverse transcriptase inhibitor whose trough concentrations differed between the co-infected and mono-infected groups. PI median plasma Cmin values were not different in the two groups, except for lopinavir, with a lower Cmin in the co-infected group than in the HIV-infected group (median 3673 versus 5990 ng/mL, P = 0.04), and nelfinavir, with significantly higher concentrations in the co-infected group. Seventy-five percent of co-infected patients scoring F4, 33% of those scoring F0–F3 and 12% of HIV-infected patients were underdosed (P = 0.02). Co-infected patients receiving an NNRTI had a higher plasma Cmin than HIV-infected patients; median Cmin was 3583 versus 1494 ng/mL (P = 0.025) and 5331 versus 3954 ng/mL (P = 0.10) for efavirenz and nevirapine, respectively. Overall, there was a greater proportion of co-infected patients with high concentrations of both NNRTIs (15/23) compared with HIV mono-infected patients (5/21) (P = 0.008), especially in co-infected patients with an advanced liver fibrosis stage. Median plasma Cmin values differed significantly between HIV and HIV-HCV co-infected patients for abacavir, lopinavir and efavirenz. NNRTIs were strongly overdosed in HIV-HCV co-infected patients.Keywords
This publication has 27 references indexed in Scilit:
- Antiretroviral TherapyClinical Pharmacokinetics, 2008
- Assessing the Impact of Substance use and Hepatitis Coinfection on Atazanavir and Lopinavir Trough Concentrations in HIV-Infected Patients During Therapeutic Drug MonitoringTherapeutic Drug Monitoring, 2007
- Liver‐related mortality in human‐immunodeficiency‐virus‐infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study)*Journal of Viral Hepatitis, 2006
- Liver Injury and Changes in Hepatitis C Virus (HCV) RNA Load Associated with Protease Inhibitor-Based Antiretroviral Therapy for Treatment-Naive HCV-HIV-Coinfected Patients: Lopinavir-Ritonavir versus NelfinavirClinical Infectious Diseases, 2005
- Short Communication: Changes in Nevirapine Plasma Concentrations Over Time and Its Relationship with Liver Enzyme ElevationsAIDS Research and Human Retroviruses, 2005
- Influence of Liver Fibrosis on Highly Active Antiretroviral Therapy--Associated Hepatotoxicity in Patients with HIV and Hepatitis C Virus CoinfectionClinical Infectious Diseases, 2005
- Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patientsJournal of Antimicrobial Chemotherapy, 2005
- Hepatotoxicity of AntiretroviralsDrug Safety, 2005
- Incidence of Liver Injury After Beginning Antiretroviral Therapy with Efavirenz or NevirapineHIV Research & Clinical Practice, 2003
- Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infectionsHepatology, 2002